5-LO Inhibitor Combination Therapy for CML Resistance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for myeloproliferative disorders, particularly Chronic Myelogenous Leukemia (CML), face challenges due to resistance to kinase inhibitors and the progression of the disease from chronic to blast crisis, necessitating new therapeutic methods to effectively target leukemia stem cells and manage resistance.

Innovation Solution

Administering a therapeutically effective amount of an arachidonate 5-lipoxygenase (5-LO) inhibitor, such as zileuton, alone or in combination with tyrosine kinase inhibitors like imatinib, to treat myeloproliferative disorders, including CML, by targeting leukemia stem cells and addressing resistance to kinase inhibitors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If tyrosine kinase inhibitors are used to treat CML, then the chronic phase can be controlled, but the disease progresses to blast crisis and patients develop resistance

Engineering Contradiction:

Improvetreatment effectivenessVSAvoiddisease progression time

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent combines 5-LOX inhibitors with tyrosine kinase inhibitors to create a multi-target therapeutic approach. This combination targets both differentiated leukemia cells (via TKI) and leukemia stem cells (via 5-LOX inhibition), thereby controlling chronic phase while preventing progression to blast crisis and overcoming resistance

Inventive Principle:

Principle #5Merging (Combining)

2Productivity

If kinase inhibitors are used to treat CML, then leukemia cells are inhibited, but leukemia stem cells remain resistant and drive disease progression

Engineering Contradiction:

Improveleukemia cell inhibitionVSAvoidstem cell targeting

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent introduces 5-LOX inhibitors as an intermediary mechanism that specifically targets leukemia stem cells, which are resistant to conventional TKI therapy. The 5-LOX inhibition pathway provides an alternative mechanism to eliminate the stem cell population that drives disease progression and resistance

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS8669289B2Methods and compositions relating to hematologic malignancies

Publication Date: 2014.03.11 JACKSON LAB THE

AI summary

Methods of treating a subject having, or at risk of having, a myeloproliferative disorder are provided according to embodiments of the present invention which include administering a therapeutically effective amount of an arachidonate 5-lipoxygenase (5-LO) inhibitor to the subject. Combinations of therapeutic agents are administered according to embodiments of the present invention. In some embodiments, two or more 5-LO inhibitors are administered to a subject to treat a myeloproliferative disorder. In further embodiments, at least one 5-LO inhibitor and at least one additional therapeutic agent are administered to a subject to treat a myeloproliferative disorder. Methods of inhibiting leukemia stem cells are provided according to embodiments of the present invention which include contacting leukemia stem cells with an effective amount of an arachidonate 5-lipoxygenase inhibitor.